Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company is headquartered in Boston, Massachusetts and currently employs 134 full-time employees. The company went IPO on 2021-06-24. The firm is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. The company has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Follow-Up Questions
Who is the CEO of Monte Rosa Therapeutics Inc?
Dr. Markus Warmuth is the President of Monte Rosa Therapeutics Inc, joining the firm since 2020.
What is the price performance of GLUE stock?
The current price of GLUE is $9.97, it has decreased 0.76% in the last trading day.
What are the primary business themes or industries for Monte Rosa Therapeutics Inc?
Monte Rosa Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Monte Rosa Therapeutics Inc market cap?
Monte Rosa Therapeutics Inc's current market cap is $615.9M
Is Monte Rosa Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 9 analysts have made analyst ratings for Monte Rosa Therapeutics Inc, including 5 strong buy, 8 buy, 2 hold, 0 sell, and 5 strong sell
